These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1107354)
21. [Studies of crossed immunity between different serotypes of dysentery bacilli and the keratoconjunctivitis-positive, lactoso-negative strain 47552 deprived of Shigella agglutinogen]. Ciufeco C Arch Roum Pathol Exp Microbiol; 1969; 28(2):389-94. PubMed ID: 4925072 [No Abstract] [Full Text] [Related]
22. Immunoblot analysis of antibody responses to Shigella dysenteriae type 1 infection. Sinha AK; Chakraborti S Indian J Med Res; 1992 May; 95():112-4. PubMed ID: 1380491 [TBL] [Abstract][Full Text] [Related]
23. Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis. Islam D; Wretlind B; Hammarström L; Christensson B; Lindberg AA APMIS; 1996; 104(7-8):563-74. PubMed ID: 8920810 [TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. McKenzie R; Venkatesan MM; Wolf MK; Islam D; Grahek S; Jones AM; Bloom A; Taylor DN; Hale TL; Bourgeois AL Vaccine; 2008 Jun; 26(26):3291-6. PubMed ID: 18468742 [TBL] [Abstract][Full Text] [Related]
25. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. Islam MS; Stimson WH J Clin Lab Immunol; 1990 Sep; 33(1):11-6. PubMed ID: 1966939 [TBL] [Abstract][Full Text] [Related]
26. Animal toxicity of Shigella dysenteriae cytotoxin: evidence that the neurotoxic, enterotoxic, and cytotoxic activities are due to one toxin. Eiklid K; Olsnes S J Immunol; 1983 Jan; 130(1):380-4. PubMed ID: 6336624 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of a new recombinant IpaC from Shigella dysenteriae type I in guinea pig as a vaccine candidate. Malaei F; Hesaraki M; Saadati M; Ahdi AM; Sadraeian M; Honari H; Nazarian S Iran J Immunol; 2013 Jun; 10(2):110-7. PubMed ID: 23811550 [TBL] [Abstract][Full Text] [Related]
28. Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I. Sayem MA; Ahmad SM; Rekha RS; Sarker P; Agerberth B; Talukder KA; Raqib R J Health Popul Nutr; 2011 Oct; 29(5):429-37. PubMed ID: 22106748 [TBL] [Abstract][Full Text] [Related]
29. Purification and biological characterization of shiga toxin from Shigella dysenteriae 1. Brown JE; Griffin DE; Rothman SW; Doctor BP Infect Immun; 1982 Jun; 36(3):996-1005. PubMed ID: 7047403 [TBL] [Abstract][Full Text] [Related]
30. A monoclonal antibody to Shigella dysenteriae serotype 13 cross-reacting with Shiga toxin. Qadri F; Azim T; Hossain A; Islam D; Mondol G; Faruque SM; Albert MJ FEMS Microbiol Lett; 1993 Mar; 107(2-3):343-7. PubMed ID: 8472916 [TBL] [Abstract][Full Text] [Related]
32. The pathogenesis of Shigella diarrhea. I. Enterotoxin production by Shigella dysenteriae I. Keusch GT; Grady GF; Mata LJ; McIver J J Clin Invest; 1972 May; 51(5):1212-8. PubMed ID: 4560429 [TBL] [Abstract][Full Text] [Related]
33. Investigation of the antigenic composition of the cells and the exotoxin of Sh. dysenteriae (Shiga) by agar immunoelectrophoresis and polyacrylamide gel disc electrophoresis. Belaya YA; Kostenko LS; Gekker VD J Hyg Epidemiol Microbiol Immunol; 1977; 21(3):285-94. PubMed ID: 75222 [TBL] [Abstract][Full Text] [Related]
34. Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. Donohue-Rolfe A; Keusch GT; Edson C; Thorley-Lawson D; Jacewicz M J Exp Med; 1984 Dec; 160(6):1767-81. PubMed ID: 6392471 [TBL] [Abstract][Full Text] [Related]
35. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1. Fontaine A; Arondel J; Sansonetti PJ Infect Immun; 1988 Dec; 56(12):3099-109. PubMed ID: 3053452 [TBL] [Abstract][Full Text] [Related]
36. [Neutralizing action of human blood preparations on Shigella enterotoxins and choleragen]. Kamzolkina NB; Borisova IV; Mitskevich ED Zh Mikrobiol Epidemiol Immunobiol; 1984 Jun; (6):64-8. PubMed ID: 6205524 [TBL] [Abstract][Full Text] [Related]
37. Release of interleukin-2 induced by a major antigenic outer membrane protein of Shigella dysenteriae type 1 in natural infection. Chakrabarti S; Sinha AK Microbios; 1997; 92(371):123-32. PubMed ID: 9589610 [TBL] [Abstract][Full Text] [Related]
38. Shigella dysenteriae 1 cytotoxin: periplasmic protein releasable by polymyxin B and osmotic shock. Donohue-Rolfe A; Keusch GT Infect Immun; 1983 Jan; 39(1):270-4. PubMed ID: 6295958 [TBL] [Abstract][Full Text] [Related]
39. [The role of Shigella dysenteriae toxin formation at different stages in the forming of the cellular immune response in experimental animals]. Nikolaeva TN; Bondarenko VM; Pronin AV Zh Mikrobiol Epidemiol Immunobiol; 1997; (2):6-10. PubMed ID: 9245145 [TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of Shigella diarrhea. VII. Evidence for a cell membrane toxin receptor involving beta1 leads to 4-linked N-acetyl-D-glucosamine oligomers. Keusch GT; Jacewicz M J Exp Med; 1977 Aug; 146(2):535-46. PubMed ID: 327017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]